MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Vendor advances, gross$1,756K Cash and cashequivalents$3,675K Vendor advances, net$625K Prepaid expenses andother current assets$143K Deferred offering costs$1,279K Intangible assets, net$22K Less accumulatedamortization$1,131K Total current assets$4,443K Total other assets$1,301K Total assets$5,744K Total liabilities andshareholders equity$5,744K Total shareholdersequity$5,313K Total currentliabilities$431K Accumulated deficit-$15,916K Additional paid-in capital$21,208K Accounts payable andaccrued expenses$431K Common stock, par value0.001, 100,000,000...$21K
Balance Sheet

Kairos Pharma, LTD. (KAPA)

Kairos Pharma, LTD. (KAPA)

source: myfinsight.com